Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.73 |
| ▸ | BRD4 | O60885 | 4/20 | 0.63 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.54 |
| ▸ | BRD2 | P25440 | 1/20 | 0.54 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.54 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.54 |
| ▸ | EED | O75530 | 1/20 | 0.46 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.46 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.46 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23030221 | 0.85 | EZH2 (0.62) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL21423087 | 0.84 | EZH2 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL31124661 | 0.84 | EZH2 (0.82) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL20991985 | 0.82 | EZH2 (0.52) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL18863744 | 0.78 | EZH2 (0.78) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL2592706 | 0.78 | EZH2 (0.64) | EZH2BRD4EZH1EEDSUZ12 | |
| SCHEMBL28795469 | 0.78 | EZH2 (0.64) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL19570159 | 0.78 | EZH2 (0.46) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL28795486 | 0.78 | EZH2 (1.00) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL17970320 | 0.78 | EZH2 (0.77) | EZH2BRD4EZH1BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | FONDATION ASILE DES AVEUGLES (CH) | 2026-05-26 | — | — | US | claimed |
| WO-2025105519-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF STEROID-INDUCED CATARACT | 경상국립대학교병원 | 2025-05-22 | — | — | WO | claimed |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | WISTAR INST (US) | 2025-01-09 | — | — | US | claimed |
| EP-3823671-B1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FOND ASILE DES AVEUGLES (CH) | 2024-02-07 | — | — | EP | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| US-20220193056-A1 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | CASE WESTERN RESERVE UNIVERSITY | 2022-06-23 | — | — | US | claimed |
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-08-19 | — | — | US | claimed |
| US-20210213013-A1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FONDATION ASILE DES AVEUGLES (CH) | 2021-07-15 | — | — | US | claimed |
| US-20210023077-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2021-01-28 | — | — | US | claimed |
| WO-2019195443-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190192521-A1 | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | WISTAR INST (US) | 2019-06-27 | — | — | US | claimed |
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-05-09 | — | — | US | claimed |
| WO-2018034801-A1 | METHODS OF TREATING ARID1A-MUTATED CANCERS WITH HDAC6 INHIBITORS AND EZH2 INHIBITORS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-22 | — | — | WO | claimed |
| WO-2017192290-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC DRUGS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2017-11-09 | — | — | WO | claimed |
| US-20160091485-A1 | MARKERS FOR EZH2 INHIBITORS | THE BROAD INSTITUTE, INC. (US) | 2016-03-31 | — | — | US | claimed |
| WO-2014176047-A1 | MARKERS FOR EZH2 INHIBITORS | NOVARTIS AG (CH) | 2014-10-30 | — | — | WO | claimed |
| US-12629364-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2025105519-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF STEROID-INDUCED CATARACT | 경상국립대학교병원 | 2025-05-22 | — | — | WO | disclosed |
| US-20160091485-A1 | MARKERS FOR EZH2 INHIBITORS | THE BROAD INSTITUTE, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| WO-2014176047-A1 | MARKERS FOR EZH2 INHIBITORS | NOVARTIS AG (CH) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023077-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | EZH2 2/4885BRD4 90/4885EZH1 31/4885 |
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | EZH2, EZH1, EED | EZH2 1/4885BRD4 695/4885EZH1 2/4885 |
| US-20190192521-A1 | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | EZH2, HDAC6, HDAC1 | EZH2 1/4885BRD4 35/4885EZH1 14/4885 |
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | EZH2 2/4885BRD4 186/4885EZH1 17/4885 |
| US-12629364-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | EZH2, CARM1, PRMT6 | EZH2 1/4885BRD4 292/4885EZH1 10/4885 |
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | EZH2 2/4885BRD4 195/4885EZH1 16/4885 |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | EZH2 2/4885BRD4 89/4885EZH1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.